Immunotherapy of brain metastases: breaking a “dogma”

Until very few years ago, the oncology community dogmatically excluded any clinical potential for immunotherapy in controlling brain metastases. Therefore, despite the significant therapeutic efficacy of monoclonal antibodies to immune check-point(s) across a wide range of tumor types, patients with...

Descripción completa

Detalles Bibliográficos
Autores principales: Di Giacomo, Anna Maria, Valente, Monica, Cerase, Alfonso, Lofiego, Maria Fortunata, Piazzini, Francesca, Calabrò, Luana, Gambale, Elisabetta, Covre, Alessia, Maio, Michele
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6798349/
https://www.ncbi.nlm.nih.gov/pubmed/31623643
http://dx.doi.org/10.1186/s13046-019-1426-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6798349/
https://www.ncbi.nlm.nih.gov/pubmed/31623643
http://dx.doi.org/10.1186/s13046-019-1426-2

Ejemplares similares